Dr. Tolaney Discusses Patient Selection for Platinum-Based Therapy in TNBC

Video

Sara M. Tolaney, MD, MPH, physician, instructor in medicine, Harvard Medical School, medical oncologist, Dana-Farber Cancer Institute, discusses patient selection for platinum-based therapy in triple-negative breast cancer (TNBC).

Tolaney believes the standard of care will remain standard chemotherapy for triple-negative disease. However, she feels it is important to learn which patients could benefit from the additional platinum-based therapy.

A common question is whether or not a patient with aBRCAmutation should receive platinum-based therapy. In previous studies, the pathological complete response rates were high for patients with this mutation, so it may be beneficial for this therapy to be incorporated intoBCRAcarriers in the future.

Sara M. Tolaney, MD, MPH, physician, instructor in medicine, Harvard Medical School, medical oncologist, Dana-Farber Cancer Institute, discusses patient selection for platinum-based therapy in triple-negative breast cancer (TNBC).

Related Videos
Video 3 - "Managing Toxicities and Adverse Reactions in HR+/Her2-Low mBC Therapies"
Video 2 - "EMERALD: Underscoring Key Elacestrant Data + Subgroup Analyses for Informed Therapy Selection"
Video 1 - "A 62-Year-Old Woman with HR+ HER2-low Metastatic Breast Cancer and Lung, Liver, and Bone Metastases and Using Biomarker Testing to Guide Treatment Selection"
Related Content